CR20220136A - Proteínas de fijación multiespecíficas para tratamiento contra el cáncer - Google Patents

Proteínas de fijación multiespecíficas para tratamiento contra el cáncer

Info

Publication number
CR20220136A
CR20220136A CR20220136A CR20220136A CR20220136A CR 20220136 A CR20220136 A CR 20220136A CR 20220136 A CR20220136 A CR 20220136A CR 20220136 A CR20220136 A CR 20220136A CR 20220136 A CR20220136 A CR 20220136A
Authority
CR
Costa Rica
Prior art keywords
proteins
binding proteins
against cancer
treatment against
multispecific binding
Prior art date
Application number
CR20220136A
Other languages
English (en)
Inventor
Susanne Hipp
Marcio Lasaro
Vladimir H Voynov
Philip Nicholas Gorman
Justin M Scheer
Paul Adam
Michael Dziegelewski
Rajkumar Ganesan
Priyanka Gupta
Pankaj Gupta
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68136317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20220136(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CR20220136A publication Critical patent/CR20220136A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a proteínas de fijación a B7H6/CD3 novedosas. La invención también se refiere a ácidos nucleicos que codifican tales proteínas; a métodos para preparar tales proteínas; a células huésped que expresan o son capaces de expresar tales proteínas; a composiciones que comprenden tales proteínas; y a usos de tales proteínas o tales composiciones, en particular, con fines terapéuticos en el campo de las enfermedades cancerosas.
CR20220136A 2019-10-02 2020-10-01 Proteínas de fijación multiespecíficas para tratamiento contra el cáncer CR20220136A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19201200 2019-10-02
PCT/EP2020/077586 WO2021064137A2 (en) 2019-10-02 2020-10-01 Multi-specific binding proteins for cancer treatment

Publications (1)

Publication Number Publication Date
CR20220136A true CR20220136A (es) 2022-05-27

Family

ID=68136317

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220136A CR20220136A (es) 2019-10-02 2020-10-01 Proteínas de fijación multiespecíficas para tratamiento contra el cáncer

Country Status (24)

Country Link
US (2) US11732045B2 (es)
EP (1) EP4038100A2 (es)
JP (2) JP7387885B2 (es)
KR (1) KR20220075383A (es)
CN (1) CN114641496B (es)
AR (1) AR120138A1 (es)
AU (1) AU2020358893A1 (es)
BR (1) BR112022004047A2 (es)
CA (1) CA3153372A1 (es)
CL (1) CL2022000664A1 (es)
CO (1) CO2022003552A2 (es)
CR (1) CR20220136A (es)
DO (1) DOP2022000060A (es)
EC (1) ECSP22019193A (es)
IL (1) IL291817A (es)
JO (1) JOP20220079A1 (es)
MX (1) MX2022004042A (es)
MY (1) MY209387A (es)
PE (1) PE20221412A1 (es)
PH (1) PH12022550693A1 (es)
SA (1) SA522432139B1 (es)
TW (1) TWI878355B (es)
UA (1) UA130106C2 (es)
WO (1) WO2021064137A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3180665A1 (en) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
JP2024511465A (ja) 2021-03-26 2024-03-13 イナート・ファルマ・ソシエテ・アノニム Ｎｋ細胞エンゲージングのためにサイトカインに融合したｎｋｐ４６結合性部位、がん抗原結合性部位を含む多特異性タンパク質
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
MX2023014647A (es) 2021-06-09 2024-01-31 Innate Pharma Proteinas de union a nkp46 multiespecificas.
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
CN114395047B (zh) * 2021-12-07 2023-11-07 合肥天港免疫药物有限公司 双特异性抗体及其应用
CN114395043B (zh) * 2021-12-07 2023-07-11 合肥天港免疫药物有限公司 Ncr3lg1抗体及其应用
CN114395045B (zh) * 2021-12-07 2023-06-09 合肥天港免疫药物有限公司 B7h6抗体及其应用
TW202432545A (zh) 2022-10-26 2024-08-16 德商百靈佳殷格翰國際股份有限公司 可活化sting之雜環化合物
TW202432115A (zh) 2022-10-26 2024-08-16 德商百靈佳殷格翰國際股份有限公司 可活化sting之雜環化合物
KR20250091261A (ko) 2022-10-26 2025-06-20 베링거 인겔하임 인터내셔날 게엠베하 Sting를 활성화할 수 있는 헤테로사이클릭 화합물
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US168A (en) 1837-04-17 Improvement in fire-arms
US5731A (en) 1848-08-22 Elisha k
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69305085D1 (de) 1992-08-10 1996-10-31 Alcan Aluminium Ltd Geländer
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
DE69420137T2 (de) 1993-06-03 1999-12-23 Therapeutic Antibodies, Inc. Herstellung von antikörperfragmenten
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
CN101684158A (zh) 2001-01-17 2010-03-31 特鲁比昂药品公司 结合域-免疫球蛋白融合蛋白
US20050214857A1 (en) 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
NL1019562C2 (nl) 2001-12-13 2003-06-17 Heineken Tech Services Klepsamenstel voor gebruik bij drankafgifte.
US8764654B2 (en) 2008-03-19 2014-07-01 Zin Technologies, Inc. Data acquisition for modular biometric monitoring system
JP5686953B2 (ja) * 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
PL2860192T3 (pl) 2005-10-12 2018-03-30 Morphosys Ag Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38
WO2009046407A2 (en) 2007-10-04 2009-04-09 Zymogenetics, Inc. B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
FI20090280L (fi) 2009-07-17 2011-01-18 Kone Corp Hissijärjestely ja menetelmä hissikorin liikuttamiseksi hissikuilussa
WO2011075861A1 (en) 2009-12-23 2011-06-30 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
US9587021B2 (en) 2011-05-21 2017-03-07 Macrogenics, Inc. CD3-binding molecules capable of binding to human and non-human CD3
HUE031828T2 (en) 2011-06-23 2017-08-28 Ablynx Nv Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain
PE20141522A1 (es) 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
CA3182462A1 (en) 2011-10-10 2013-04-18 Xencor, Inc. A method for purifying antibodies
ES2719495T5 (en) * 2012-05-07 2025-09-10 Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
CA2878587A1 (en) * 2012-07-23 2014-01-30 Zymeworks Inc. Immunoglobulin constructs comprising selective pairing of the light and heavy chains
JP7082604B2 (ja) * 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
CN109310764B (zh) * 2016-04-15 2022-01-14 达特茅斯大学理事会 高亲和力b7-h6抗体和抗体片段
UA127200C2 (uk) 2016-05-18 2023-06-07 Бьорінгер Інгельхайм Інтернаціональ Гмбх Молекула антитіла до pd1
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白

Also Published As

Publication number Publication date
CA3153372A1 (en) 2021-04-08
WO2021064137A3 (en) 2021-05-14
JP7387885B2 (ja) 2023-11-28
TW202128756A (zh) 2021-08-01
CN114641496B (zh) 2026-01-02
CN114641496A (zh) 2022-06-17
EP4038100A2 (en) 2022-08-10
US20230340130A1 (en) 2023-10-26
MY209387A (en) 2025-07-07
JP2024020414A (ja) 2024-02-14
JP7809680B2 (ja) 2026-02-02
SA522432139B1 (ar) 2024-08-29
MX2022004042A (es) 2022-05-02
PE20221412A1 (es) 2022-09-20
TWI878355B (zh) 2025-04-01
AU2020358893A1 (en) 2022-03-31
BR112022004047A2 (pt) 2022-05-24
CO2022003552A2 (es) 2022-04-19
PH12022550693A1 (en) 2023-03-27
JP2022551081A (ja) 2022-12-07
ECSP22019193A (es) 2022-04-29
CL2022000664A1 (es) 2023-01-06
US20210107983A1 (en) 2021-04-15
JOP20220079A1 (ar) 2023-01-30
KR20220075383A (ko) 2022-06-08
IL291817A (en) 2022-06-01
WO2021064137A2 (en) 2021-04-08
AR120138A1 (es) 2022-02-02
UA130106C2 (uk) 2025-11-12
US11732045B2 (en) 2023-08-22
DOP2022000060A (es) 2022-05-31

Similar Documents

Publication Publication Date Title
CO2022003552A2 (es) Proteínas de fijación multiespecíficas para tratamiento contra el cáncer
CL2021002094A1 (es) Moléculas de anticuerpo para el tratamiento del cáncer. (divisional solicitud 201803153)
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
BR112022019020A2 (pt) Proteínas de fusão de il12 mascaradas e métodos de uso das mesmas
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
MX2026002469A (es) Nuevas moleculas de acido nucleico artificiales
MX2019006727A (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
DOP2015000110A (es) Anticuerpos anti-ceacam5 y usos de estos
EP4378962A3 (en) Anti-cancer fusion polypeptide
BR112017010110A2 (pt) anticorpos contra cd73 e usos do mesmo
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
MX390894B (es) Polipéptido de fusión anti-cáncer.
MX2020011914A (es) Anticuerpos anti-dll3 y usos de los mismos.
MX2021000401A (es) Nuevas proteinas de fusion especificas para cd137 y pd-l1.
MX377781B (es) Composiciones y metodos para diagnostico y tratamiento del cancer.
CO2024005918A2 (es) Anticuerpos de unión a cd30 y cd3
CL2019003074A1 (es) Variantes de la proteína bmp7 humana.
WO2022236276A3 (en) Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof
WO2021043810A8 (en) Anti-fucosyl-gm1 antibodies
AR115506A1 (es) Proteínas de fijación multiespecífica para el tratamiento del cáncer